NCT05787860View on ClinicalTrials.gov

Ruxolitinib in Seborrheic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

45

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

January 26, 2024

Study Completion Date

January 26, 2024

Conditions

Seborrheic Dermatitis

Interventions

DRUG

Ruxolitinib 1.5% Cream

topical ruxolitinib 1.5% cream twice daily for 4 weeks

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

Icahn School of Medicine at Mount Sinai

OTHER